NASDAQ
14.00USD
0.00 (0.00%)
We have scored 7 news catalysts on Ventyx Biosciences, Inc. (VTYX) over the past 12 months. The biggest single-day move next to one of them came Jan 7, 2026, when VTYX closed +36.6%: “Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases”. Coverage across the window leans mixed (average ticker sentiment +0.04). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1B
P/E
—
EPS
—
Beta
1.27
52W range
0.783-25
Day range
14.00–14.00
Open
14.00
Prev close
14.00
Volume
5.4M
Avg volume
3.8M
Dividend
0.00
IPO
2021-10-21
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Ventyx Biosciences, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Ventyx Biosciences, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for VTYX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated conditions, including psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. Among its pipeline assets is VTX002, an oral sphingosine 1 phosphate receptor 1 (S1P1) modulator, which has advanced to Phase II clinical studies for the treatment of ulcerative colitis. Additionally, VTX2735, a peripherally targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor, is in Phase I development, intended to combat systemic inflammatory diseases affecting cardiovascular, hepatic, renal, and rheumatologic systems. Furthermore, Ventyx is engaged in the development of CNS-penetrant NLRP3 inhibitors, with the objective of providing therapies for neurological ailments such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Founded in 2018, Ventyx Biosciences, Inc. is headquartered in Encinitas, California.
